Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Pancreatic Cancer Starkly Illustrates Challenges of Developing Targeted Therapies

February 4th 2014

A recent study determined that it would take 6.7 years on average to enroll enough patients with pancreatic cancer for the trials that opened in 2011-a tall order considering that the 5-year relative survival rate for those diagnosed with pancreatic ductal adenocarcinoma is only 6%.

Targeting CD30: Research Focuses on Potential for Expanded Role in Hematologic Malignancies

January 24th 2014

The cytokine receptor CD30 was identified as an attractive anticancer target more than 30 years ago

OncLive Adds Winship Cancer Institute of Emory University to its Strategic Alliance Partnership Program

January 22nd 2014

OncLive will work with Georgia's only NCI-designated cancer center to support its efforts to conduct innovative, multidisciplinary research and translate that knowledge into excellent patient care.

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

Conclusion: Future Direction of Breast Cancer Treatment

January 22nd 2014

Preventing Skeletal-Related Events in Breast Cancer

January 22nd 2014

Chemotherapeutics in Metastatic Breast Cancer

January 22nd 2014

CDK4/6 Inhibitors in Metastatic Breast Cancer

January 22nd 2014

Next Steps for Everolimus in Metastatic Breast Cancer

January 22nd 2014

Upfront Treatment of HR-Positive MBC

January 22nd 2014

Case Study: HER2-Positive Oligometastatic Breast Cancer

January 22nd 2014

Phase III Clinical Trials in HER2-Positive Breast Cancer

January 22nd 2014

Novel Drug Development in Breast Cancer

January 22nd 2014

Role of Lapatinib in HER2-Positive Breast Cancer

January 22nd 2014

Recommendations for Optimal HER2 Testing in Breast Cancer

January 22nd 2014

T-DM1 in HER2-Positive Metastatic Breast Cancer

January 22nd 2014

PIK3CA Mutations in HER2-Positive Breast Cancer

January 22nd 2014

Frontline Pertuzumab for Metastatic Breast Cancer

January 22nd 2014

Treating Low-Risk HER2-Positive Breast Cancer

January 22nd 2014

Overview of HER2-Targeted Therapies in Breast Cancer

January 22nd 2014